Volition – executive interview

Published on 15 November 2021

Volition is a multi-national epigenetics company that applies its Nucleosomics platform through subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases, including some cancers and diseases associated with NETosis, such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present. Volition is primarily focused on diagnostics and monitoring in humans but also has a subsidiary focused on animals.

In this video, chief executive officer Cameron Reynolds discusses Volition’s third-quarter 2021 financial and operational results. During the period, the company advanced term-sheet negotiations with three large multi-national veterinary companies on potential worldwide licensing/distribution arrangements, expanded its intellectual property portfolio, made significant progress with its Nu.Q NETs development and made strong advances towards new product launches and licensing in both the human and veterinary spaces.

Share this with friends and colleagues